Zacks Research Equities Analysts Cut Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at Zacks Research dropped their FY2024 earnings per share estimates for Theravance Biopharma in a report released on Monday, April 15th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of ($0.89) per share for the year, down from their previous forecast of ($0.87). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.84) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at $0.84 EPS.

Several other research analysts have also recently issued reports on TBPH. BTIG Research started coverage on Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price target on the stock. Evercore ISI cut Theravance Biopharma from an “outperform” rating to an “inline” rating in a report on Monday, January 8th.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $9.20 on Wednesday. Theravance Biopharma has a 12 month low of $8.21 and a 12 month high of $11.98. The stock has a market cap of $446.75 million, a price-to-earnings ratio of -9.48 and a beta of 0.36. The stock’s 50 day moving average price is $9.00 and its 200 day moving average price is $9.66.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The firm had revenue of $17.57 million for the quarter, compared to the consensus estimate of $17.49 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. UBS Group AG increased its holdings in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,101 shares in the last quarter. Point72 Middle East FZE purchased a new position in Theravance Biopharma during the 4th quarter worth approximately $41,000. Tower Research Capital LLC TRC grew its position in Theravance Biopharma by 116.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,015 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 2,157 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Theravance Biopharma by 324.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 4,402 shares in the last quarter. Finally, Royal Bank of Canada grew its position in Theravance Biopharma by 33.8% during the 2nd quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,649 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.